## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

#	2

APPLIC.	NT: ITOH, Yasuaki et al.
SERIAL	NO. Based on PCT/JP0003221
FILED:	Herewith
FOR:	"NOVEL POLYPEPTIDE"
	CERTIFICATE OF EXPRESS MAIL
enclosed) sufficient Trademar	ereby certify that this paper (along with any paper referred to as being attached or s being deposited with the United States Postal Service on the date shown below with costage as Express mail in an envelope addressed to the: Commissioner of Patents and is, 2900 Crystal Drive, Arlington, VA 22202. Express Mail No EL 895421612 US.  wember 20, 2001  By:  Carren L. Mundee
	ence Commissioner for Patents on, D.C. 20231
SUBM	ISSION OF "SEQUENCE LISTING," COMPUTER READABLE COPY, AND/OR AMENDMENT PERTAINING THERETO FOR BIOTECHNOLOGY INVENTION CONTAINING NOVEL POLOYPEPTIDE SEQUENCE
	(check and complete this item, if applicable)
1. [] Th	is replies to the Office Letter DATED
in	ese papers are filed before the office letter issues, adequate identificationof the original papers should be made, e.g., ldition to the name of the inventor and title of invention, the filing date based on the "Express Mail" procedure, erial number from the return post card or the attorney's docket number added.
	[] A copy of the Office Letter is enclosed.

IDENTIFICATION OF PERSON MAKING STATEMENT

(type or print name of person signing below)

2. I, <u>CARA Z. LOWEN</u>

## 3. Submitted herewith is/are

(check each item as applicable)

- A. [X] "Sequence Listing(s)" for the Novel Polypeptide sequence(s) in this application. Each "Sequence Listing" is assigned a separate identifier as required in 37 C.F.R. § 1.821(c) and 37 C.F.R. §§ 1.822 and 1.823.
- B. [ ] An amendment to the description and/or claims, wherein reference is made to the sequence by use of the assigned identifier, as required in 37 C.F.R. § 1.821(d).
- C. [X] A copy of each "Sequence Listing" submitted for this application in computer readable form, in accordance with the requirements of 37 C.F.R. §§ 1.821(e) and 1.824.
- D. [] Please transfer to this application, in accordance with 37 C.F.R. § 1.821(e), the computer readable copy(ies) from applicant's other application identified as follows:

The Computer readable form(s) of applicant's other application corresponds to the "Sequence Identifier(s)" of the application as follows:

Computer Readable Form "Sequence Identifier" (other application) (this application)
SEQ ID NO: SEQ ID NO: 1-10

NOTE: "If the computer readable form of a new application is to be identical with the computer readable form of another application of the applicant on file in the Office, reference maybe made to the other application and computer readable form in lieu of filing a duplicate computer readable form in the new application. The new application shall be accompanied by a letter making such reference to the other application and computer readable form, both of which shall be completely identified." 37 C.F.R. § 1.821(e).

E. [X] A statement that the content of each "Sequence Listing" submitted and each computer readable copy are the same, as required in 37 C.F.R. § 1.821(g).

(Submission-"NOVEL POLYPEPTIDE" Sequence—page 2 of 5)

- [ ] Because the tement is not made by a person resistered to practice before the Office, the Statement is verified as Equired in 37 C.F.R. § 1.821(b).
  F. [X] Because this submission is made in fulfilling the requirement under 37 C.F.R. § 1.821(g), a statement that the submission includes no new matter.
  [ ] Because the statement is not made by a person registered to practice before the Office, the statement is verified, as required in 37 C.F.R. §
  - STATEMENT THAT "SEQUENCE LISTING"
    AND COMPUTER READABLE COPY ARE THE SAME
    AND/OR THAT PAPERS SUBMITTED INCLUDES NO NEW MATTER
- 4. I hereby state:

(complete applicable item A and/or B)

- A. [x] Each computer readable form submitted in this application, including those forms requested to be transferred from applicant's other application, is the same as the "Sequence Listing" to which it is indicated to relate.
- B. [] All papers accompanying this submission, or for which a request for transfer from applicants' other application, introduce no new matter.

## **STATUS**

- 5. Applicant is
  - [ ] a small entity. A statement:
    [ ] is attached.

1.821(g).

- [ ] was already filed.
- [X] other than a small entity.

## **EXTENSION OF TERM**

6. NOTE: "Extension of Time in Patent Cases (Supplement Amendments) If a timely and complete response has been filed after a Non-Final Office Action, an extension of time is not required to permit filing and/or entry of an additional amendment after expiration of the shortened statutory period.

If a timely response has been filed after a Final Office Action, an extension of time is required to permit filing and/or entry of a Notice of Appeal or filing and/or entry of an additional amendment after expiration of the shortened statutory period unless the timely-filed response placed the application in condition for allowance. Of course, if a

7.	_	The proceedings herein are for a patent application and the provisions of 37 C.F.R. $\S 1.136$ apply.		
	(a) [ ]			as applicable) of time under 37 C.F.R. § 1.136 (fees: 37 I number of months checked below:
		Extension	Fee for other than	Fee for
		(months)	small entity	small entity
	[]	one month	\$110.00	\$ 55.00
		two months	\$380.00	\$ 190.00
		three months	\$870.00	\$ 435.00
	įį	four months	\$1,360.00	\$ 680.00
			Fee \$	
If a	an add	itional extensior		lease consider this a petition therefor.
		(c	heck and complete the ne	ext item, if applicable)
		fee paid		nths has already been secured, and the is deducted from the total fee due for now requested.
Ex	tensio	n fee due with th	is request \$	
			OR	
	(b) [X ] Applicant believes that no extension of term is required. However, this conditional petition is being made to provide for the possibility that applicant has inadvertently overlooked the need for a petition and fer for extension of time.			
			FEE PAYN	MENT
8.	[ ] At	tached is a checl	k in the sum of \$	·
			the stransmittal is attached	um of \$ d.
			FEE DEFIC	IENCY
9.				

NOTE: If there is a fee deficiency and there is no authorization to charge an account, additional fees are necessary to cover the

additional time consumed in making up the original deficiency. If the maximum, six-month period has expired before

(Submission-"NOVEL POLYPEPTIDE" Sequence—page 4 of 5)

apply these charges pri	or to action on the cases. Auth the Notice of April 7, 1986, 1065	orization to charge the deposit account for any fee deficiency
10. [X] If any addition 04-1105	onal extension and/or	fee is required, charge Account No
	SIGNA	TURE(s)
DATE: NN 20,	<u>Z6</u> 01	Cara Z. Lowen, 38,227 Attorney for Applicants DIKE, BRONSTEIN, ROBERTS & CUSHMAN Intellectual Property Practice
		Group of
		EDWARDS & ANGELL, LLP P.O. Box 9169
		Boston, MA 02209  [ ] Inventor [ ] Assignee of complete interest [ ] Person authorized to sign on behalf of assignee
Tel. No.: (617) 439-4444		[X] Practitioner of record
Reg. No. 38,227		[ ] Filed under Rule 34(a) [ ] Registration No.
[]	Other	

cted, the application is held abandoned. In those

lays are encountered in returning the papers to the

ances where authorization to

D finance Branch in order to

BOS2\_182989.1

the deficiency is noted and

charge is included, processi